TREAKISYM Market

“TREAKISYM Market Size, Forecast, and Drug Insight – 2032” report offers an in-depth analysis of both the market and emerging insights regarding TREAKISYM for the treatment of Diffuse Large B-cell lymphoma (DLBCL) in Japan market. A detailed picture of the TREAKISYM in Japan for the study period 2019 –2032 is provided in this report, along with a detailed description of the TREAKISYM. The report provides insights about the mechanism of action, dosage, and administration, as well as research and development, including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments, including the TREAKISYM market forecast analysis in Japan, SWOT, analysts’ views, a comprehensive overview of market competitors, and a brief about other emerging therapies.

Drug Summary:

TREAKISYM (bendamustine hydrochloride) contains bendamustine hydrochloride, an alkylating drug, as the active ingredient. Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown. It is a cytocide anticancer drug first used in Germany in the 1970s and is widely approved in more than 50 countries with indications for low-grade non-Hodgkin lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. In the United States, the drug has been approved by the US FDA and is marketed as Treanda for treating chronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin’s lymphoma. TREAKISYM has become an essential drug (standard drug) in the treatment of R/R low-grade NHL and MCL since its October 2010 approval. Following its December 2016 approval for the additional indication of first-line low-grade NHL and MCL treatment, it is expected to become widely used for this treatment.

Moreover, the drug achieved favorable results from a Phase III study in R/R DLBCL, with the overall response rate, which was the primary endpoint of the trial, exceeding expectations and submitted a partial change application for its marketing approval for TREAKISYM in May 2020. Since its incorporation, SymBio has focused on implementing a product lifecycle management strategy to maximize the business value of TREAKISYM. As a part of this strategy, the company has pursued the expansion of approved indications.

Scope of the Report 

The report provides insights into:

• A comprehensive product overview includes the TREAKISYM description, mechanism of action, dosage and administration, and research and development activities in diffuse large B-cell lymphoma (DLBCL).
• Elaborated details on TREAKISYM regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TREAKISYM research and development activities in DLBCL across Japan.
• The report also covers the patent information with expiry timeline around TREAKISYM.
• The report contains forecasted sales of TREAKISYM for DLBCL till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DLBCL.
• The report also features the SWOT analysis with analyst views for TREAKISYM in DLBCL .

 Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities' websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

TREAKISYM Analytical Perspective by DelveInsight

• In-depth TREAKISYM Market Assessment

This report provides a detailed market assessment of TREAKISYM for Diffuse Large B-cell lymphoma (DLBCL) in Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• TREAKISYM Clinical Assessment

The report provides the clinical trials information of TREAKISYM for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.

 Report Highlights 

• In the coming years, the market scenario for Diffuse Large B-cell lymphoma (DLBCL) is set to change due to the extensive research and incremental healthcare spending worldwide, which would expand the market size to enable the drug manufacturers to penetrate more into the market. 
•  Companies are developing therapies that focus on novel approaches to treat/improve disease conditions, assess challenges, and seek opportunities that could influence TREAKISYM dominance.
•  Other emerging products for DLBCL are expected to give tough market competition to TREAKISYM, and the launch of late-stage emerging therapies in the near future will significantly impact the market. 
•  A detailed description of regulatory milestones and developmental activities provides the current development scenario of TREAKISYM in DLBCL.
•  Our in-depth analysis of the forecasted sales data of TREAKISYM from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of TREAKISYM in DLBCL. 

 Key Questions

• What is the product type, route of administration, and mechanism of action of TREAKISYM?
•  What is the clinical trial status of the study related to TREAKISYM in Diffuse Large B-cell lymphoma (DLBCL) and study completion date?
• What are the key collaborations, mergers, acquisitions, licensing, and other activities related to the TREAKISYM development?
• What are the key designations that have been granted to TREAKISYM for DLBCL?
• What is the forecasted market scenario of TREAKISYM for DLBCL?
• What are the forecasted sales of TREAKISYM in Japan? 
• What are the other emerging products available and how are these giving competition to TREAKISYM for DLBCL?
• Which are the late-stage emerging therapies under development for the treatment of DLBCL?"